Key result
Xin-Ke-Shu significantly reversed the over-expressions of PLA2 IIA, CaMK II, and Pro-Caspase-3 and regulated metabolic perturbations in isoproterenol-induced myocardial infarction rats.
Why the study?
Does Xin-Ke-Shu inhibit myocardium Ca2+ overloading and metabolic alterations in isoproterenol-induced myocardial infarction models?
Does Xin-Ke-Shu inhibit myocardium Ca2+ overloading and metabolic alterations in isoproterenol-induced myocardial infarction models?
Xin-Ke-Shu protects against isoproterenol-induced myocardial infarction in preclinical models by inhibiting the Ca2+ overloading mechanism and regulating associated metabolic pathways.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Xin-Ke-Shu in isoproterenol-induced MI models; does not yet inform clinical practice.
Xin-Ke-Shu (XKS) is a traditional Chinese patent medicine used for treatment of coronary heart diseases in China. However, its mechanism of action is still unclear. In this paper, the mediation of XKS on the isoproterenol (ISO)-induced myocardial infarction (MI) rat were evaluated based on a tissue-targeted metabonomics in vitro/vivo. The result indicated that twelve metabolic pathways were involved in the therapeutic effect of XKS in vivo, where seven pathways were associated with the Ca(2+) overloading mechanism. In agreement with regulation on metabolic variations, XKS markedly reversed the over-expressions of three involved proteins including phospholipase A2 IIA (PLA2 IIA), calcium/calmodulin-dependent protein kinase II (CaMK II) and Pro-Caspase-3. The metabolic regulations of XKS on H9c2 cell also partially confirmed its metabolic effect. These metabolic characteristics in vitro/vivo and western blotting analysis suggested that XKS protected from MI metabolic perturbation major via inhibition of Ca(2+) overloading mechanism. Furthermore, 11 active ingredients of XKS exerted steady affinity with the three proteins through the molecular docking study. Our findings indicate that the metabonomics in vitro/vivo combined with western blotting analysis offers the opportunity to gain insight into the comprehensive efficacy of TCMs on the whole metabolic network.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2016) studied Isoproterenol-induced myocardial infarction (n=24). Xin-Ke-Shu vs. Isoproterenol alone was evaluated on Expressions of PLA2 IIA, CaMK II and Pro-Caspase-3 (p=<0.05). Xin-Ke-Shu significantly reversed the over-expressions of PLA2 IIA, CaMK II, and Pro-Caspase-3 and regulated metabolic perturbations in isoproterenol-induced myocardial infarction rats.
Synapse has enriched 10 related papers. Consider them for comparative context: